GHRH analog peptide (research-stage GH secretagogue)
DAC:GRF
A growth-hormone-releasing hormone analog studied for GH axis stimulation; human pharmacokinetic data exist but broad clinical evidence is limited.
- Evidence:
- Limited human evidence
- Status:
- Not FDA-approved
- Reviewed:
- 2026-08-03
Also known as: DAC:GRF, CJC-1295 without DAC
What is DAC:GRF?
A growth-hormone-releasing hormone analog studied for GH axis stimulation; human pharmacokinetic data exist but broad clinical evidence is limited.
This profile is educational. It organizes publicly discussed research context for DAC:GRF and related naming aliases — it is not a treatment guide.
Proposed mechanism
Binds GHRH receptors on pituitary somatotrophs, stimulating pulsatile or sustained GH release depending on DAC conjugation.
Mechanism language on PepGuide describes how researchers discuss pathways. Proposed mechanisms can change as evidence evolves.
Current research notes
Human evidence grade: Limited human evidence
Preclinical evidence grade: Moderate human evidence
CJC-1295 without DAC provides shorter GH pulses; CJC-1295 with DAC (separate entry) extends half-life via albumin binding. Human PK studies confirmed GH and IGF-1 elevation. WADA prohibits GHRH analogs. Not FDA approved for general use. Often combined with ghrelin mimetics in research discussions.
Key uncertainties
- Clinical benefit beyond GH elevation
- Long-term safety
Research areas being studied
- GH axis research
- Body composition
- Recovery research
Being studied for a topic is not the same as proven benefit in that topic. Prefer primary literature for study design, endpoints, and limitations.
Safety & side-effect notes
Reported or discussed adverse effects
- Injection-site reactions
- Headache
- Flushing reported
Additional risks & considerations
- GH-axis related theoretical risks
- WADA prohibited
- Unregulated products
Regulatory status
Not FDA-approved
Regulatory framing here is educational and can lag policy changes. Check official sources for current status.
Frequently asked questions
What is DAC:GRF?
A growth-hormone-releasing hormone analog studied for GH axis stimulation; human pharmacokinetic data exist but broad clinical evidence is limited.
How does DAC:GRF work (proposed mechanism)?
Binds GHRH receptors on pituitary somatotrophs, stimulating pulsatile or sustained GH release depending on DAC conjugation.
What is DAC:GRF being researched for?
DAC:GRF has been discussed in research contexts including: GH axis research, Body composition, Recovery research.
What does current evidence say about DAC:GRF?
Limited human evidence. CJC-1295 without DAC provides shorter GH pulses; CJC-1295 with DAC (separate entry) extends half-life via albumin binding. Human PK studies confirmed GH and IGF-1 elevation. WADA prohibits GHRH analogs. Not FDA approved for general use. Often combined with ghrelin mimetics in research discussions.
What safety considerations are noted for DAC:GRF?
Reported or discussed considerations include: Injection-site reactions; Headache; Flushing reported; GH-axis related theoretical risks; WADA prohibited; Unregulated products. This is educational information, not medical advice.
References & sources
- Teichman SL et al. (2006). Prolonged stimulation of growth hormone by CJC-1295 — J Clin Endocrinol Metab. Evidence type: human.
Prefer interactive tools? Open the PepGuide library entry for DAC:GRF or ask PepGuide AI.
Educational and research information only. PepGuide does not sell or prescribe peptides, diagnose conditions, or provide personalized medical advice. Evidence summaries may include early-stage, animal, or limited human research — none of that is a substitute for primary literature or clinician guidance.